Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Condition: Stomatitis; Oral Mucositis
MeSH terms: Mucositis; Stomatitis
Intervention: SNX-1012 (meclocycline sulfosalicylate); placebo
Intervention description: tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days; Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
Intervention MeSH terms: Meclocycline
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 81.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT)
      regimens and by radiation to the head and neck. The purpose of this study is to determine the
      effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM)
      according to World Health Organization (WHO) criteria.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Naive to focal radiation therapy in the head and neck regions for cancer prior to CT
             Cycle 1. Subjects with prior or concomitant radiation therapy to areas other than the
             head and neck may be enrolled.

          -  Histologically confirmed diagnosis of breast or lung cancer (NSCLC or SCLC)

          -  Chemotherapy regimen containing AC ± T or EC ± T (for breast cancer), cisplatin or
             carboplatin (for NSCLC or SCLC), or doxorubicin (for SCLC)

          -  Subjects will receive the same regimen and dose of CT in the OM Treatment CT Cycle as
             was administered in the immediately preceding CT Cycle.

          -  Subjects will have had OM of WHO Grade of greater than or equal to 2 during CT Cycle 1
             or Cycle 2

          -  Subjects 18 years and older

          -  Karnofsky Performance Score >=60

          -  Baseline laboratory assessments:

        Hemoglobin (Hgb) level >= 9 g/dL Absolute neutrophil count (ANC) >= 1.5 x 10 to the 9/L
        Platelet count >= 100 x 10 to the 9/L Serum bilirubin level <= 1.5 times institutional
        upper limit of normal (ULN) Serum aspartate aminotransferase (AST) and/or alanine
        aminotransferase (ALT) level <= 2 times above ULN

          -  Females of childbearing potential must have a negative serum or urine pregnancy test
             result at the screening visit prior to the start of Cycle 1 and at the visit scheduled
             for <= 48 hours prior to the start of the OM Treatment CT Cycle

          -  Subjects with reproductive capability must agree to practice adequate contraception
             methods (males must use condoms or be surgically sterilized; females must be
             surgically sterilized, post-menopausal for at least 1 year, or use an appropriate
             double barrier method, prescribed birth control oral contraceptive, patch, implant, or
             injection during the course of the study and for up to 30 days after completion of
             study assessments)

          -  Absence of other serious concurrent medical illness

          -  Psychologically able to participate and comply with study requirements

        Exclusion Criteria:

          -  Prior history of oral mucositis with previous chemotherapy treatment

          -  Previous treatment with an anthracycline agent (other than low-dose neoadjuvant
             therapy)

          -  Active liver disease or serum AST and/or ALT level > 2 times above ULN

          -  Currently receiving an investigational agent, planning to receive an investigational
             agent during the study period, or received an investigational agent within 30 days of
             the first dose of SNX-1012

          -  Use of an immunosuppressive regimen of systemic corticosteroids

          -  Unwilling/unable to receive periodic oral assessments by a study evaluator or unable
             to complete the daily self-reported outcome questionnaire

          -  Pregnant or breast-feeding women

          -  Bronchoalveolar carcinoma

          -  Metastases to the central nervous system

          -  Prior or planned focal radiation therapy in the head or neck regions for the treatment
             of cancer (prior radiation to areas other than the head and neck is permitted)

          -  Presence of active or history of chronic oral mucosal disease

          -  Presence or history of any other primary malignancy (curatively treated nonmelanoma
             skin cancer is allowed)

          -  History of chronic liver disease

          -  Active hepatitis A or B

          -  Unable to receive CT during the OM Treatment CT Cycle at the same regimen and/or dose
             as in the immediately preceding CT cycle.

          -  Known sensitivity to tetracyclines

          -  Known to be seropositive for HIV or HCV

          -  Use of an immunosuppressive regimen of systemic corticosteroids.

          -  Current alcohol dependence or drug abuse

          -  Psychological, social or familial or geographical reasons that would hinder or prevent
             study visits

          -  Compromised ability to give written informed consent and/or to comply with study
             procedures